DTA (Dopaminergic Therapy for Anhedonia) Study

PHASE4CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 29, 2021

Primary Completion Date

October 11, 2023

Study Completion Date

October 11, 2023

Conditions
DepressionAnhedonia
Interventions
DRUG

Carbidopa Levodopa

Patients will receive L-DOPA at doses ranging from 150 to 450 mg administered at a ratio of 1 mg carbidopa for every 4 mg L-DOPA. Starting dose is 150 mg/day with dose escalation 150 mg/day per week to a final dose of 450 mg/day

DRUG

Placebo

A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 1 placebo tablet matching the Carbidopa Levodopa tablet.

Trial Locations (1)

30322

Emory University Hospital, Atlanta

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Emory University

OTHER

NCT04723147 - DTA (Dopaminergic Therapy for Anhedonia) Study | Biotech Hunter | Biotech Hunter